Proceeding report of the Second Symposium on Hidradenitis Suppurativa Advances (SHSA) 2017

Eran Shavit; Afsaneh Alavi; Falk G. Bechara; Richard G. Bennett; Marc Bourcier; Ricardo Cibotti; Steven Daveluy; John W. Frew; Amit Garg; Iltefat Hamzavi; Lauren K. Hoffman; Jenny Hsaio; Joslyn Sciacca Kirby; Hadar Lev-Tov; Erin Martinez; Robert Micheletti; Haley B. Naik; Aude Nassif; Cynthia Nicholson; Angie Parks-Miller; Zarine Patel; Vincent Piguet; Mayur Ramesh; Barry Resnik; Christopher Sayed; Gregory Schultz; Aamir Siddiqui; Jerry Tan; Ximena Wortsman; Michelle A. Lowes

doi:10.1111/exd.13849

Proceeding report of the Second Symposium on Hidradenitis Suppurativa Advances (SHSA) 2017

Eran Shavit
, Afsaneh Alavi
, Falk G. Bechara
, Richard G. Bennett
, Marc Bourcier
, Ricardo Cibotti
, Steven Daveluy
, John W. Frew
, Amit Garg
, Iltefat Hamzavi
, Lauren K. Hoffman
, Jenny Hsaio
, Joslyn Sciacca Kirby
, Hadar Lev-Tov
, Erin Martinez
, Robert Micheletti
, Haley B. Naik
, Aude Nassif
, Cynthia Nicholson
, Angie Parks-Miller

Zarine Patel, Vincent Piguet, Mayur Ramesh, Barry Resnik, Christopher Sayed, Gregory Schultz, Aamir Siddiqui, Jerry Tan, Ximena Wortsman, Michelle A. Lowes

Research output: Contribution to journal › Article › peer-review

13 Scopus citations

Abstract

The 2nd Annual Symposium on Hidradenitis Suppurativa Advances (SHSA) took place on 03-05 November 2017 in Detroit, Michigan, USA. This symposium was a joint meeting of the Hidradenitis Suppurativa Foundation (HSF Inc.) founded in the USA, and the Canadian Hidradenitis Suppurativa Foundation (CHSF). This was the second annual meeting of the SHSA with experts from different disciplines arriving from North America, Europe and Australia, in a joint aim to discuss most recent innovations, practical challenges and potential solutions to issues related in the management and care of Hidradenitis Suppurativa patients. The last session involved clinicians, patients and their families in an effort to educate them more about the disease.

Original language	English (US)
Pages (from-to)	94-103
Number of pages	10
Journal	Experimental Dermatology
Volume	28
Issue number	1
DOIs	https://doi.org/10.1111/exd.13849
State	Published - Jan 2019
Externally published	Yes

Bibliographical note

Funding Information:
AA has received consulting fees from AbbVie, Actelion, Celgene, Galderma, GSK, InflaRx, Janssen, Kyowa Incyte Leo Pharma Novartis Pfizer Regeneron Roche Sanofi2 Genzyme UCB Valeant. FGB has received consulting fees from AbbVie. He is on the advisory Board for AbbVie, Janssen, and is an investigator for AbbVie, Janssen, Novartis and InflaRx. RGB has no conflicts of interest. MB is a Speaker for Astellas, AbbVie, Amgen, Eli-Lilly, La Roche-Posay, LEO Pharma, Janssen, Novartis, Pfizer, Merck, Valeant. He is on the Advisory Board for AbbVie, Amgen, Bausch Health, Eli-Lilly, La Roche-Posay, LEO Pharma, Janssen, Novartis, Pfizer, Merck, Valeant, and he is also an investigator of clinical trials for AbbVie, Amgen, Astellas, Basilea, Biogen, Celgene, Eli-Lilly, Galderma, Janssen, Johnson & Johnson, Janssen, Merck, Novartis, Ortho Biotech, Pfizer. RC has no conflicts of interest. SD is the speaker for AbbVie, and an investigator for Regeneron and InflaRx. JF has no conflicts of interest. AG has received consulting fees from AbbVie, Asana Biosciences, Janssen, Pfizer, UCB; grant support from AbbVie, UCB, National Psoriasis Foundation.IHH is the President of the HS Foundation, in a non-compensated role, an Investigator for; Lenicura (equipment received, no grant), AbbVie (grant paid to institution), Jansen (grant paid to institution), is or has been a consultant with fees received by UCB, Novartis, Incyte, Pfizer. LKH has no conflicts of interest. JH has no conflicts of interest. JSK is a speaker for AbbVie and has received consulting fees from Incyte and ChemoCentryx.HLT is the founder of Dermveda, Inc. and is an investigator for Factor Therapeutics, Molnlycke, BSN, TissuTech, Ilkos and Medline. EM has no conflicts of interest. RM has no conflicts of interest. MAL has received consulting fees from AbbVie, Xbiotech, Janssen, BSN: consultant/ Ad boards, and consultant on clinical trial for Incyte. HBN has received a research grant from Abbvie. AN has received travel grant from AbbVie, MSD. CN has no conflicts of interest. APM is a consultant for non-marketing materials for AbbVie and has received fees, serves or has served on an Advisory Board for AbbVie and has received fees, and serves or has served as a consultant for BSN and has received fees, is the President & Founding Director of Hope for HS in a non-compensated role and is an employee of the HS Foundation. ZP has no conflicts of interest. VP reports receiving educational grants from Abbvie, Celgene, Janssen, Naos, Lilly, Sanofi, Valeant, and nonfinancial support from La Roche-Posay. VP undertakes personal advisory work with Pfizer, AbbVie, Janssen, UCB, Novartis, Almirall and Celgene. MR has no conflicts of interest. BR has no conflicts of interest. CS is the speaker for Abbvie Inc. and for Norvartis, an investigator for UCB, and serves both as an investigator and consultant for InflaRx. GS in the last 12 months has been a consultant for Medline and has received research grants from Medline, B Braun, Next Science, Avadim, and Smith & Nephew. ES has no conflicts of interest. AS in the last

Publisher Copyright:
© 2018 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd

Keywords

hidradenitis suppurativa
symposium

Publisher link

10.1111/exd.13849

Find It

Find It at U of M Libraries

Cite this

Shavit, E., Alavi, A., Bechara, F. G., Bennett, R. G., Bourcier, M., Cibotti, R., Daveluy, S., Frew, J. W., Garg, A., Hamzavi, I., Hoffman, L. K., Hsaio, J., Kirby, J. S., Lev-Tov, H., Martinez, E., Micheletti, R., Naik, H. B., Nassif, A., Nicholson, C., ... Lowes, M. A. (2019). Proceeding report of the Second Symposium on Hidradenitis Suppurativa Advances (SHSA) 2017. Experimental Dermatology, 28(1), 94-103. https://doi.org/10.1111/exd.13849

Shavit, E, Alavi, A, Bechara, FG, Bennett, RG, Bourcier, M, Cibotti, R, Daveluy, S, Frew, JW, Garg, A, Hamzavi, I, Hoffman, LK, Hsaio, J, Kirby, JS, Lev-Tov, H, Martinez, E, Micheletti, R, Naik, HB, Nassif, A, Nicholson, C, Parks-Miller, A, Patel, Z, Piguet, V, Ramesh, M, Resnik, B, Sayed, C, Schultz, G, Siddiqui, A, Tan, J, Wortsman, X & Lowes, MA 2019, 'Proceeding report of the Second Symposium on Hidradenitis Suppurativa Advances (SHSA) 2017', Experimental Dermatology, vol. 28, no. 1, pp. 94-103. https://doi.org/10.1111/exd.13849

@article{1687a9873e464777b741b0adfe594860,

title = "Proceeding report of the Second Symposium on Hidradenitis Suppurativa Advances (SHSA) 2017",

abstract = "The 2nd Annual Symposium on Hidradenitis Suppurativa Advances (SHSA) took place on 03-05 November 2017 in Detroit, Michigan, USA. This symposium was a joint meeting of the Hidradenitis Suppurativa Foundation (HSF Inc.) founded in the USA, and the Canadian Hidradenitis Suppurativa Foundation (CHSF). This was the second annual meeting of the SHSA with experts from different disciplines arriving from North America, Europe and Australia, in a joint aim to discuss most recent innovations, practical challenges and potential solutions to issues related in the management and care of Hidradenitis Suppurativa patients. The last session involved clinicians, patients and their families in an effort to educate them more about the disease.",

keywords = "hidradenitis suppurativa, symposium",

author = "Eran Shavit and Afsaneh Alavi and Bechara, \{Falk G.\} and Bennett, \{Richard G.\} and Marc Bourcier and Ricardo Cibotti and Steven Daveluy and Frew, \{John W.\} and Amit Garg and Iltefat Hamzavi and Hoffman, \{Lauren K.\} and Jenny Hsaio and Kirby, \{Joslyn Sciacca\} and Hadar Lev-Tov and Erin Martinez and Robert Micheletti and Naik, \{Haley B.\} and Aude Nassif and Cynthia Nicholson and Angie Parks-Miller and Zarine Patel and Vincent Piguet and Mayur Ramesh and Barry Resnik and Christopher Sayed and Gregory Schultz and Aamir Siddiqui and Jerry Tan and Ximena Wortsman and Lowes, \{Michelle A.\}",

note = "Funding Information: AA has received consulting fees from AbbVie, Actelion, Celgene, Galderma, GSK, InflaRx, Janssen, Kyowa Incyte Leo Pharma Novartis Pfizer Regeneron Roche Sanofi2 Genzyme UCB Valeant. FGB has received consulting fees from AbbVie. He is on the advisory Board for AbbVie, Janssen, and is an investigator for AbbVie, Janssen, Novartis and InflaRx. RGB has no conflicts of interest. MB is a Speaker for Astellas, AbbVie, Amgen, Eli-Lilly, La Roche-Posay, LEO Pharma, Janssen, Novartis, Pfizer, Merck, Valeant. He is on the Advisory Board for AbbVie, Amgen, Bausch Health, Eli-Lilly, La Roche-Posay, LEO Pharma, Janssen, Novartis, Pfizer, Merck, Valeant, and he is also an investigator of clinical trials for AbbVie, Amgen, Astellas, Basilea, Biogen, Celgene, Eli-Lilly, Galderma, Janssen, Johnson \& Johnson, Janssen, Merck, Novartis, Ortho Biotech, Pfizer. RC has no conflicts of interest. SD is the speaker for AbbVie, and an investigator for Regeneron and InflaRx. JF has no conflicts of interest. AG has received consulting fees from AbbVie, Asana Biosciences, Janssen, Pfizer, UCB; grant support from AbbVie, UCB, National Psoriasis Foundation.IHH is the President of the HS Foundation, in a non-compensated role, an Investigator for; Lenicura (equipment received, no grant), AbbVie (grant paid to institution), Jansen (grant paid to institution), is or has been a consultant with fees received by UCB, Novartis, Incyte, Pfizer. LKH has no conflicts of interest. JH has no conflicts of interest. JSK is a speaker for AbbVie and has received consulting fees from Incyte and ChemoCentryx.HLT is the founder of Dermveda, Inc. and is an investigator for Factor Therapeutics, Molnlycke, BSN, TissuTech, Ilkos and Medline. EM has no conflicts of interest. RM has no conflicts of interest. MAL has received consulting fees from AbbVie, Xbiotech, Janssen, BSN: consultant/ Ad boards, and consultant on clinical trial for Incyte. HBN has received a research grant from Abbvie. AN has received travel grant from AbbVie, MSD. CN has no conflicts of interest. APM is a consultant for non-marketing materials for AbbVie and has received fees, serves or has served on an Advisory Board for AbbVie and has received fees, and serves or has served as a consultant for BSN and has received fees, is the President \& Founding Director of Hope for HS in a non-compensated role and is an employee of the HS Foundation. ZP has no conflicts of interest. VP reports receiving educational grants from Abbvie, Celgene, Janssen, Naos, Lilly, Sanofi, Valeant, and nonfinancial support from La Roche-Posay. VP undertakes personal advisory work with Pfizer, AbbVie, Janssen, UCB, Novartis, Almirall and Celgene. MR has no conflicts of interest. BR has no conflicts of interest. CS is the speaker for Abbvie Inc. and for Norvartis, an investigator for UCB, and serves both as an investigator and consultant for InflaRx. GS in the last 12 months has been a consultant for Medline and has received research grants from Medline, B Braun, Next Science, Avadim, and Smith \& Nephew. ES has no conflicts of interest. AS in the last Publisher Copyright: {\textcopyright} 2018 John Wiley \& Sons A/S. Published by John Wiley \& Sons Ltd",

year = "2019",

month = jan,

doi = "10.1111/exd.13849",

language = "English (US)",

volume = "28",

pages = "94--103",

journal = "Experimental Dermatology",

issn = "0906-6705",

publisher = "John Wiley and Sons Inc.",

number = "1",

}

TY - JOUR

T1 - Proceeding report of the Second Symposium on Hidradenitis Suppurativa Advances (SHSA) 2017

AU - Shavit, Eran

AU - Alavi, Afsaneh

AU - Bechara, Falk G.

AU - Bennett, Richard G.

AU - Bourcier, Marc

AU - Cibotti, Ricardo

AU - Daveluy, Steven

AU - Frew, John W.

AU - Garg, Amit

AU - Hamzavi, Iltefat

AU - Hoffman, Lauren K.

AU - Hsaio, Jenny

AU - Kirby, Joslyn Sciacca

AU - Lev-Tov, Hadar

AU - Martinez, Erin

AU - Micheletti, Robert

AU - Naik, Haley B.

AU - Nassif, Aude

AU - Nicholson, Cynthia

AU - Parks-Miller, Angie

AU - Patel, Zarine

AU - Piguet, Vincent

AU - Ramesh, Mayur

AU - Resnik, Barry

AU - Sayed, Christopher

AU - Schultz, Gregory

AU - Siddiqui, Aamir

AU - Tan, Jerry

AU - Wortsman, Ximena

AU - Lowes, Michelle A.

N1 - Funding Information: AA has received consulting fees from AbbVie, Actelion, Celgene, Galderma, GSK, InflaRx, Janssen, Kyowa Incyte Leo Pharma Novartis Pfizer Regeneron Roche Sanofi2 Genzyme UCB Valeant. FGB has received consulting fees from AbbVie. He is on the advisory Board for AbbVie, Janssen, and is an investigator for AbbVie, Janssen, Novartis and InflaRx. RGB has no conflicts of interest. MB is a Speaker for Astellas, AbbVie, Amgen, Eli-Lilly, La Roche-Posay, LEO Pharma, Janssen, Novartis, Pfizer, Merck, Valeant. He is on the Advisory Board for AbbVie, Amgen, Bausch Health, Eli-Lilly, La Roche-Posay, LEO Pharma, Janssen, Novartis, Pfizer, Merck, Valeant, and he is also an investigator of clinical trials for AbbVie, Amgen, Astellas, Basilea, Biogen, Celgene, Eli-Lilly, Galderma, Janssen, Johnson & Johnson, Janssen, Merck, Novartis, Ortho Biotech, Pfizer. RC has no conflicts of interest. SD is the speaker for AbbVie, and an investigator for Regeneron and InflaRx. JF has no conflicts of interest. AG has received consulting fees from AbbVie, Asana Biosciences, Janssen, Pfizer, UCB; grant support from AbbVie, UCB, National Psoriasis Foundation.IHH is the President of the HS Foundation, in a non-compensated role, an Investigator for; Lenicura (equipment received, no grant), AbbVie (grant paid to institution), Jansen (grant paid to institution), is or has been a consultant with fees received by UCB, Novartis, Incyte, Pfizer. LKH has no conflicts of interest. JH has no conflicts of interest. JSK is a speaker for AbbVie and has received consulting fees from Incyte and ChemoCentryx.HLT is the founder of Dermveda, Inc. and is an investigator for Factor Therapeutics, Molnlycke, BSN, TissuTech, Ilkos and Medline. EM has no conflicts of interest. RM has no conflicts of interest. MAL has received consulting fees from AbbVie, Xbiotech, Janssen, BSN: consultant/ Ad boards, and consultant on clinical trial for Incyte. HBN has received a research grant from Abbvie. AN has received travel grant from AbbVie, MSD. CN has no conflicts of interest. APM is a consultant for non-marketing materials for AbbVie and has received fees, serves or has served on an Advisory Board for AbbVie and has received fees, and serves or has served as a consultant for BSN and has received fees, is the President & Founding Director of Hope for HS in a non-compensated role and is an employee of the HS Foundation. ZP has no conflicts of interest. VP reports receiving educational grants from Abbvie, Celgene, Janssen, Naos, Lilly, Sanofi, Valeant, and nonfinancial support from La Roche-Posay. VP undertakes personal advisory work with Pfizer, AbbVie, Janssen, UCB, Novartis, Almirall and Celgene. MR has no conflicts of interest. BR has no conflicts of interest. CS is the speaker for Abbvie Inc. and for Norvartis, an investigator for UCB, and serves both as an investigator and consultant for InflaRx. GS in the last 12 months has been a consultant for Medline and has received research grants from Medline, B Braun, Next Science, Avadim, and Smith & Nephew. ES has no conflicts of interest. AS in the last Publisher Copyright: © 2018 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd

PY - 2019/1

Y1 - 2019/1

N2 - The 2nd Annual Symposium on Hidradenitis Suppurativa Advances (SHSA) took place on 03-05 November 2017 in Detroit, Michigan, USA. This symposium was a joint meeting of the Hidradenitis Suppurativa Foundation (HSF Inc.) founded in the USA, and the Canadian Hidradenitis Suppurativa Foundation (CHSF). This was the second annual meeting of the SHSA with experts from different disciplines arriving from North America, Europe and Australia, in a joint aim to discuss most recent innovations, practical challenges and potential solutions to issues related in the management and care of Hidradenitis Suppurativa patients. The last session involved clinicians, patients and their families in an effort to educate them more about the disease.

AB - The 2nd Annual Symposium on Hidradenitis Suppurativa Advances (SHSA) took place on 03-05 November 2017 in Detroit, Michigan, USA. This symposium was a joint meeting of the Hidradenitis Suppurativa Foundation (HSF Inc.) founded in the USA, and the Canadian Hidradenitis Suppurativa Foundation (CHSF). This was the second annual meeting of the SHSA with experts from different disciplines arriving from North America, Europe and Australia, in a joint aim to discuss most recent innovations, practical challenges and potential solutions to issues related in the management and care of Hidradenitis Suppurativa patients. The last session involved clinicians, patients and their families in an effort to educate them more about the disease.

KW - hidradenitis suppurativa

KW - symposium

UR - https://www.scopus.com/pages/publications/85060021309

UR - https://www.scopus.com/pages/publications/85060021309#tab=citedBy

U2 - 10.1111/exd.13849

DO - 10.1111/exd.13849

M3 - Article

C2 - 30484907

AN - SCOPUS:85060021309

SN - 0906-6705

VL - 28

SP - 94

EP - 103

JO - Experimental Dermatology

JF - Experimental Dermatology

IS - 1

ER -

Proceeding report of the Second Symposium on Hidradenitis Suppurativa Advances (SHSA) 2017

Abstract

Bibliographical note

Keywords

Publisher link

Find It

Other files and links

Fingerprint

Cite this